RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations | Zendy

Robert Shenkar | Zendy; Changbin Shi | Zendy; Cecilia Austin | Zendy; Thomas Moore | Zendy; Rhonda Lightle | Zendy; Ying Cao | Zendy; Lingjiao Zhang | Zendy; Meijing Wu | Zendy; Hussein A. Zeineddine | Zendy; Romuald Girard | Zendy; David A. McDonald | Zendy; Autumn Rorrer | Zendy; Carol J. Gallione | Zendy; Peter Pytel | Zendy; James K. Liao | Zendy; Douglas A. Marchuk | Zendy; Issam A. Awad | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations

Author(s) -

Robert Shenkar,

Changbin Shi,

Cecilia Austin,

Thomas Moore,

Rhonda Lightle,

Ying Cao,

Lingjiao Zhang,

Meijing Wu,

Hussein A. Zeineddine,

Romuald Girard,

David A. McDonald,

Autumn Rorrer,

Carol J. Gallione,

Peter Pytel,

James K. Liao,

Douglas A. Marchuk,

Issam A. Awad

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.015013

Subject(s) - fasudil , simvastatin , medicine , rhoa , rho associated protein kinase , lesion , rho kinase inhibitor , pharmacology , pathology , kinase , biology , biochemistry , signal transduction

We sought to compare the effect of chronic treatment with commonly tolerated doses of Fasudil, a specific RhoA kinase (ROCK) inhibitor, and simvastatin (with pleiotropic effects including ROCK inhibition) on cerebral cavernous malformation (CCM) genesis and maturation in 2 models that recapitulate the human disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research